Gottlieb Alice B
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08901, USA.
J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S3-16. doi: 10.1016/j.jaad.2005.04.026.
A variety of therapeutic options are available to treat psoriasis and atopic dermatitis (AD). Local agents typically are used to treat localized and milder forms of disease, whereas phototherapy and systemic agents are used for more generalized and severe disease. Various combinations and sequences of topical or systemic therapies, or both, have been utilized in the treatment of psoriasis and, less frequently, of AD. Conventional systemic therapies for psoriasis, such as corticosteroids, oral calcineurin inhibitors, antimetabolites, and retinoids, are limited by their propensity to cause serious side effects. More recently, a number of immunobiologic agents, such as monoclonal antibodies, recombinant cytokines, and fusion proteins, have been approved by the Food and Drug Administration or are undergoing development as systemic antipsoriatic treatments. In many of these categories, a number of exciting new therapies are in development that may augment the existing armamentarium available to clinicians for the treatment of inflammatory skin diseases.
有多种治疗选择可用于治疗银屑病和特应性皮炎（AD）。局部用药通常用于治疗局限性和较轻形式的疾病，而光疗和全身用药则用于更广泛和严重的疾病。局部或全身治疗或两者的各种组合及顺序已被用于治疗银屑病，较少用于治疗AD。银屑病的传统全身治疗方法，如皮质类固醇、口服钙调神经磷酸酶抑制剂、抗代谢物和维甲酸，因其易引起严重副作用而受到限制。最近，一些免疫生物制剂，如单克隆抗体、重组细胞因子和融合蛋白，已获得美国食品药品监督管理局的批准，或正在作为全身性银屑病治疗药物进行研发。在这些类别中的许多方面，有一些令人兴奋的新疗法正在研发中，可能会增加临床医生现有的用于治疗炎症性皮肤病的手段。
